Providing a diverse range of perspectives from bullish to bearish, 7 analysts have published ratings on AnaptysBio (NASDAQ:ANAB) in the last three months. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Analysts have recently evaluated AnaptysBio and provided 12-month price targets. The average target is $54.43, accompanied by a high estimate of $75.00 and a low estimate of $30.00. Surpassing the previous average price target of $45.00, the current average has increased by 2…